SCHEMBL5314522

SCHEMBL5314522

O=C(O)C=C1CCC2(CC1)OCCO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
PTPN1 P18031 1/20 0.33
KMT2A Q03164 4/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ITGB3 P05106 1/20 0.32
ITGB1 P05556 1/20 0.32
ITGAV P06756 1/20 0.32
ITGA4 P13612 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
TSHR P16473 1/20 0.32
GAA P10253 1/20 0.31
POLB P06746 2/20 0.31
HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13327433 0.84 ALDH1A1 (0.33) ALDH1A1PTPN1KMT2AL3MBTL1TSHR
SCHEMBL1188054 0.78 KMT2A (0.37) ALDH1A1KMT2ASMN1; SMN2MEN1L3MBTL1
SCHEMBL337729 0.74 ESR2 (0.45) ALDH1A1KMT2ASMN1; SMN2MAPK1HSD17B10
SCHEMBL10000017 0.74 ALDH1A1 (0.31) ALDH1A1POLB
SCHEMBL12296797 0.74 ITGB3 (0.37) ITGB3ITGB1ITGAVITGA4TSHR
SCHEMBL5677274 0.72 ITGB3 (0.35) ITGB3ITGB1ITGAVITGA4TSHR
SCHEMBL15622089 0.72 ITGB3 (0.35) NPC1RAB9AITGB3ITGB1ITGAV
SCHEMBL12983433 0.72 ITGB3 (0.40) NPC1RAB9AITGB3ITGB1ITGAV
SCHEMBL1931711 0.72
SCHEMBL15610657 0.72 PLA2G7 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118043471-A Process for the production of (1 r,4 r) -4-substituted cyclohexane-1-amines 吉瑞工厂 2024-05-14 CN disclosed
CN-116437927-A Tetrahydrobenzodiazepine ketone compound and pharmaceutical application thereof 日本烟草产业株式会社 2023-07-14 CN disclosed
US-RE49128-E1 Hydroxyl purine compounds and applications thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2022-07-12 US disclosed
WO-2019196780-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 信达生物制药(苏州)有限公司 2019-10-17 WO disclosed
US-20180325889-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES, INC. 2018-11-15 US disclosed
US-10098885-B2 Hydroxyl purine compounds and applications thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-10-16 US disclosed
US-20170326149-A1 HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-11-16 US disclosed
US-9550793-B2 Spirocyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-01-24 US disclosed
EP-3110810-A1 PYRAZOLE AMIDE DERIVATIVE Teijin Pharma Limited (JP) 2017-01-04 EP disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 WO disclosed
US-20070265243-A1 Antibiotic-Bound Poly(Caprolactone) Polymer UNIVERSITY OF SOUTH FLORIDA (US) 2007-11-15 US disclosed
EP-1802633-A1 BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES Bayer Pharmaceuticals Corporation (US) 2007-07-04 EP disclosed
WO-2006044524-A1 BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO disclosed
EP-0993459-B1 COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE SCHERING CORP (US) 2002-11-06 EP disclosed
US-6410541-B2 BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES ADMINISTERED AS ANTITUMOR AGENTS SCHERING CORPORATION 2002-06-25 US disclosed
US-20010007870-A1 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents REMISZEWSKI STACY W (US) 2001-07-12 US disclosed
EP-0993459-A1 COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2000-04-19 EP disclosed
WO-1998057955-A1 COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE SCHERING CORPORATION (US) 1998-12-23 WO disclosed
EP-0802897-A1 NOVEL COMPOUNDS Smithkline Beecham S.p.A. (IT) 1997-10-29 EP disclosed
WO-1996021638-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM S.P.A. (IT) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326149-A1 HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF PNP, PDE2A, PDE7A ALDH1A1 265/4885PTPN1 2005/4885KMT2A 3904/4885
US-20070265243-A1 Antibiotic-Bound Poly(Caprolactone) Polymer CAPG, PGLS, GNE ALDH1A1 2039/4885PTPN1 3559/4885KMT2A 3962/4885
US-20180325889-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT ALDH1A1 219/4885PTPN1 943/4885KMT2A 1557/4885
US-20010007870-A1 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents HCCS, FNTB, CBR1 ALDH1A1 795/4885PTPN1 3470/4885KMT2A 4069/4885
US-10098885-B2 Hydroxyl purine compounds and applications thereof PNP, PDE2A, PDE7A ALDH1A1 265/4885PTPN1 2005/4885KMT2A 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.